

Remarks

Claims 1 to 21 were in the application as filed. Claims 1 to 21 were cancelled and claims 22 to 33 were added in the Preliminary Amendment filed on September 10, 2003. Claim 30 was cancelled and claims 34 to 36 were added in the Amendment filed on June 26, 2007. Claims 23, 28, and 29 were cancelled in the Amendment filed on September 14, 2007.

Claim 34 is amended to cancel the recitation of group I and II topoisomerases, fluoropyrimidines, oestrogenic hormones and androgenic hormones. Applicants reserve the right to prosecute the deleted subject matter in one or more continuation, continuation-in-part, or divisional applications.

Claim 35 is amended to change its dependency from claim 34 to claim 25.

No new matter has been added by these amendments.

As presently amended, claims 22, 24 to 27, and 31 to 36 are pending in this application.

Discussion of Allowed Claims

Applicants acknowledge, with appreciation, the Examiner's allowance of claim 26.

Applicants understand that the Examiner has withdrawn the allowance of claims 25 and 36.

Discussion of Foreign Priority

It is noted that Applicants' claims of foreign priority to French Patent Application Nos. FR 99 15031, filed November 29, 1999, and to FR 00 10561, filed August 11, 2000 have not been acknowledged.

Applicants call the Examiner's attention to parent Patent Application No. 09/722,361 (now U.S. Patent No. 6,645,964) wherein certified copies of FR 99 15031 and FR 00 10561 were filed. According to MPEP 201.14(b)(II):

Where the benefit of a foreign filing date based on a foreign application is claimed in a later filed application (i.e., a continuation, continuation-in-part, division) or in a reissue application and a certified copy of the foreign application as filed, has been filed in a parent or related application, it is not necessary to file an additional certified copy in the later application.

Acknowledgement of these documents and of Applicants' claims to priority of FR 99 15031 and FR 00 10561 is respectfully requested.

Discussion of Rejections under 35 USC § 112, Second Paragraph

Previously allowed claim 25 is presently rejected under 35 U.S.C. § 112, second paragraph, because, the Examiner alleges, said claim "is unclear as to the identity of that which applicant regards as the invention." (Office Action, page 2). The Examiner asserts that "[d]etermining whether a given disease responds or not to inhibition of 'telomerase' involves much experimentation" and that "Applicants only show the relationship of telomerase inhibition to the treatment of lung cancer." (*Id.*).

This rejection is traversed and reconsideration and withdrawal thereof are respectfully requested for the reasons given hereinbelow.

The Examiner appears to be combining the standards of enablement with those of indefiniteness. A rejection for lack of clarity is appropriate if "the language of the claim is such that a person of ordinary skill in the art could not interpret the metes and bounds of the claim so as to avoid infringement" (MPEP 2173.02). The Examiner has not indicated that any particular word or phrase in claim 25 is unclear, but merely asks "what 'success rate' determines if a particular compound is effective?" (Office Action, page 2). As stated by the Board of Patent Appeals and Interferences:

We are satisfied that the skilled worker in this art could readily optimize effective dosages and administration regimens for each of the recited utilities. As is well known, the specific dosage for a given patient under specific conditions and for a specific disease will routinely vary, but determination of the optimum amount in each case can readily be accomplished by routine procedures.

Ex parte Skuballa, 12 USPQ2d 1570, 1571 (Bd. Pat. App. & Inter. 1989).

The Examiner has not set forth reasons why one skilled in the art could not determine "a therapeutically effective amount" using standard techniques in the art. Accordingly, this phrase would be clear to one of ordinary skill in the art.

Moreover, claim 25 is directed to a method of inhibiting telomerase activity, and not to methods of treating particular diseases. A rejection based on lack of clarity should be based on the claim as written, and not on claim language unreasonably read into the claim. The rejection of claim 25 under 35 U.S.C. § 112, second paragraph, is unwarranted and should be withdrawn.

Claims 31 to 36 are rejected under 35 U.S.C. § 112, second paragraph, as being allegedly indefinite. As grounds for this rejection, the Examiner asks “What type(s) of topoisomerases is/are referred to...What fluoropyrimidines are referred to? What specific oestrogenic and androgenic hormones are being used in combination with compounds of formula I? In claim 35, what is UFT?” (Office Action, page 3).

Without acquiescing to the propriety of the rejection, and solely to advance prosecution, Applicants have deleted the recitation of the terms group I and II topoisomerases, fluoropyrimidines, oestrogenic hormones and androgenic hormones in claim 34. Therefore, the rejection as to claim 34 and claims dependent thereon is believed overcome.

As to the Examiner’s question “[w]hat is UFT,” UFT is an anti-cancer product that is a 1:4 mixture of tegafur and uracil, which is well known to those of ordinary skill in the art (See e.g., Anti-cancer Drugs, v. 11. pp. 579-582, 2000, copy attached). The rejection of claim 35, and claims dependent thereon, as it pertains to the term “UFT” is therefore unwarranted and should be withdrawn.

Discussion of Double Patenting Rejection

The Examiner has maintained the provisional double patenting rejection of claims 22, 24, and 27 on the grounds of non-statutory obviousness-type double patenting as being allegedly unpatentable over claims 1, 3, 5, and 9 of copending Application No. 10/996,637.

As this is only a provisional double-patenting rejection, Applicants will wait until this double patenting rejection is the sole remaining issue in the instant application or U.S. Patent Application No. 10/996,637, and at that time Applicants will address the obviousness-type double patenting issue.

Copending Applications

Applicants remind the Examiner of copending U.S. Patent Application Nos. 10/773,806 and 10/993,637, and respectfully request the Examiner to review the ongoing prosecution of said applications, including all Office Actions issued therein.

There being no remaining issues, this application is believed in condition for favorable reconsideration and early allowance, and such actions are earnestly solicited.

The Commissioner is hereby authorized to charge any additional fees which may be required by this paper, or credit any overpayment to Deposit Account No. 18-1982.

Respectfully submitted,

March 17, 2008
Date

Kelly L. Bender
Kelly L. Bender, Reg. No. 52,610
Attorney for Applicants

sanofi-aventis U.S. Inc.
U.S. Patent Operations
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (610) 889-8995
Telefax (908) 231-2626

sanofi-aventis Docket No. ST99049G1 US DIV

Preclinical report

Synergistic antitumoral activity of combined UFT, folinic acid and oxaliplatin against human colorectal HT29 cell xenografts in athymic nude mice

Christophe Louvet,^{1,2} Anne-Marie Coudray,¹ Christophe Tournigand,^{1,2} Sophie Prévost,^{1,3} Eric Raymond,¹ Almyer de Gramont,² Michel Chazard⁴ and Christlan Gespach¹

¹INSERM Unit 482, ²Department of Internal Medicine–Oncology and ³Department of Pathology, Hôpital St-Antoine, 184 rue du Faubourg St-Antoine, 75012 Paris, France. ⁴Oncology Clinical Research, Bristol-Myers Squibb, 92044 Paris-la-Défense, France.

This study was designed to assess the inhibition of tumor growth by oxaliplatin combined with UFT and folinic acid (FA). Growth inhibition was studied in nude mice transplanted with human colorectal HT29 tumor cell xenografts and treated for 28 days with oral UFT (20 mg/kg/day) and FA (4 mg/kg/day), i.p. oxaliplatin (10 mg/kg on day 1) or a combination of oxaliplatin, UFT and FA, or else not treated (controls). Tumor surface area and weight were recorded twice a week, and mice were sacrificed at day 28. Two separate experiments were performed for each group of 25 mice. At day 28, mean tumor weights (g) were 2.89 ± 0.22 (controls), 2.03 ± 0.14 (oxaliplatin), 2.02 ± 0.21 (UFT/FA) and 1.23 ± 0.17 (oxaliplatin+UFT/FA). For the three treatment groups, tumor weight decreases were 30.1% ($p < 0.05$), 29.9% ($p < 0.05$) and 57.5% ($p < 0.001$), respectively. Combined treatment (UFT/FA+oxaliplatin) reduced tumor weight by 39% compared to oxaliplatin alone ($p < 0.05$) or UFT/FA ($p < 0.05$). These results demonstrate the synergistic effect of the combination of oxaliplatin, UFT and FA in this HT29 cell xenograft model, and warrant further investigations in patients with metastatic colorectal cancer. [© 2000 Lippincott Williams & Wilkins.]

Key words: Folinic acid, human colorectal cancer HT29 cell xenograft, oxaliplatin, UFT.

Introduction

The oral thymidylate synthase inhibitor UFT (a mixture of tegafur and uracil, at a molar ratio of 1:4) has been

shown to be clinically active against colorectal, gastric and breast adenocarcinomas.^{1,2} Subsequent animal studies demonstrated that UFT is more active than tegafur alone and that its activity is enhanced by folinic acid.^{3,4} Two recent clinical studies in patients with metastatic colorectal cancer showed that a combination of UFT and folinic acid (FA), given orally, was as effective as the combination of 5-fluorouracil (5-FU) and FA, given as an i.v. bolus days 1–5 every month.^{5,6}

Oxaliplatin is a recently synthesized diaminocyclohexane platinum compound, which like cisplatin causes DNA-adduct formation, resulting in damage such as intrastrand cross-links covalently binding the platinum compound to guanine radicals,⁷ DNA interstrand cross-links, DNA–protein cross-links and DNA strand breaks.⁸ When oxaliplatin is used alone, it is active against various malignancies, including some which are usually resistant to cisplatin, but it was mainly developed for colorectal cancer. We previously demonstrated that 5-FU and FA enhanced oxaliplatin activity, both in preclinical studies⁹ and clinical studies.^{10,11} The present investigation was designed to characterize the antitumoral activity of UFT, FA and oxaliplatin against xenografts of human colonic HT29 cells in nude mice, regarded as a model of highly aggressive tumor progression.

Materials and methods

Chemicals

UFT and oxaliplatin were generous gifts from Bristol-Myers Squibb France (Paris, France) and Sanofi Recherche (Paris, France). FA was purchased from Sigma (St Louis, MO). All other reagents were of the purest grade available.

This work was supported by INSERM and a Research Grant from Bristol-Myers Squibb France.

Correspondence to C Louvet, Service de Médecine Interne–Oncologie, Hôpital St-Antoine, 184 rue du faubourg St-Antoine, 75012 Paris, France.

Tel: (+33) 1 49 28 23 45; Fax: (+33) 1 49 28 23 44;
E-mail: christophe.louvet@sat.ap-hop-paris.fr

Cells and culture conditions

Human colorectal cancer HT29 cells were obtained from Dr J Fogh (Sloan Kettering Institute for Cancer Research, NY) and cultured in Dulbecco's modified Eagle's medium (DMEM; Eurobio, Paris, France), supplemented with 10% heat-decomplemented fetal bovine serum (Boehringer, Mannheim, Germany), 100 U/ml penicillin, 100 µg/ml streptomycin and 8 nM glutamine. Cells were grown at 37°C in a humidified atmosphere containing 5% CO₂. The medium was renewed every 2 days and the cells were passaged twice a week by trypsin-EDTA to maintain their exponential growth.

Animals and xenografts

Female BALB/c nude mice (*nu+ / nu+*) aged 6 weeks were maintained in a pathogen-free state. Human colorectal HT29 cell xenografts (1×10^6 cells) were transplanted s.c. into the hind limb of each animal. Treatment began 14 days later, when tumors were palpable and measurable (mean tumor surface area = 33 mm²).

Treatments

After tumor occurrence, animals were allocated to four groups: control (group 1), oxaliplatin (group 2), UFT+folinic acid (group 3) and oxaliplatin+UFT+folinic acid (group 4). UFT was administered to mice via the drinking water at a concentration that would deliver 20 mg/kg/day from days 1 to 28. Likewise, FA was administered via the drinking water at a concentration delivering 4 mg/kg/day from days 1 to 28. Oxaliplatin was administered by i.p. injection on day 1 at a dosage corresponding to 10 mg/kg.

Tumor and toxicity measurements

The longest axis of each tumor and the axis perpendicular to the longest axis were measured by a caliper. Tumor size (i.e. surface area) and body weight were recorded twice a week. Successive tumor measurements were normalized in relation to the initial (baseline) measurement per animal in order to establish growth curves for each group. For each experiment, all measurements were made by the same observer.

Animals were sacrificed 28 days after treatment initiation, and tumors were excised and weighed. A specimen tumor from each group was sent for pathological examination. Tumor weight (g) per group is expressed as the mean \pm SEM.

Toxicity was evaluated in terms of mortality and the body weight ratio W_n/W_0 , where W_n is the body weight n days after the start of treatment and W_0 is the weight at the start of treatment.

Statistical analysis

As two consecutive experiments gave similar data, their results were combined and represent the average of all data for a total of 25 animals per group. Means for each group were compared by one-way analysis of variances. Barlett's test was used to verify the homogeneity of the variances and the Tukey-Kramer multiple comparison test was used for inter-group comparisons. InStat and Prism software (GraphPad, San Diego, CA) were used for statistical analyses and graphs.

Results

No adverse effect was observed in any of the three treatment groups: all the mice were alive at day 28 and mean body weight was similar in the four experimental groups (Table 1). Compared to the controls (group 1), tumor growth was slightly inhibited by UFT+FA (group 3) and oxaliplatin (group 2), with decreases in tumor size of 19 and 24%, respectively, by day 28 (Figure 1). Tumor growth inhibition by the combined treatment (group 4) at day 28 was 54% versus the controls, 45% versus UFT+FA (group 3) and 40% versus oxaliplatin (group 2).

At day 28, mean tumor weights were 2.89 ± 0.22 g in the control group, 2.03 ± 0.14 g in the oxaliplatin group, 2.02 ± 0.21 g in the UFT+FA group and 1.23 ± 0.17 g in the combined treatment group (Figure 2). Analysis of variance showed that the differences between mean tumor weights were significant ($F=12,536$; 99 d.f.; $p < 0.0001$). The Barlett test

Table 1. Side-effects of UFT plus FA, oxaliplatin and the three combined

Group	N	Body weight ratio (mean \pm SD)	Mortality
Control	25	1.01 ± 0.08	0
UFT+FA	25	1.02 ± 0.07	0
Oxaliplatin	25	1.05 ± 0.09	0
Combined treatment	25	1.01 ± 0.08	0

Side effects were evaluated in terms of body weight ratio (W_n/W_0) and mortality, where W_n is the body weight measured n days after the initial administration and W_0 is the body weight at the start of treatment. Animals were weighed twice a week. The table indicates the body weight ratio before sacrifice at day 28.




Figure 1. Growth curves of HT29 cell tumors in nude mice for the three treatment groups: UFT+FA (○), oxaliplatin (▲), or UFT+FA+oxaliplatin (□), versus the control group (■). Treatment began 14 days after HT29 cell xenografts. Measurements of tumor size, i.e. surface area, were normalized according to tumor size treatment initiation (day 0). Two separate experiments gave comparable results. This figure summarizes tumor growth in 25 animals per group.




Figure 2. Mean tumor weight (\pm SEM) after 28 days of treatment for group 1 (control), group 2 (oxaliplatin), group 3 (UFT+folinic acid) and group 4 (UFT+folinic acid+oxaliplatin). Each group comprised 25 mice.

showed that the differences between the standard deviations were not significant (Bartlett=6.648; $p=0.084$). Tumor weight decreases compared to the controls were 30% for UFT+FA ($q=4.442$; $p<0.05$), 30% for oxaliplatin ($q=4.416$; $p<0.05$) and 58% for the combined treatment ($q=8.672$; $p<0.001$). Comparisons of tumor weight in the UFT+FA and oxaliplatin

groups showed no significant difference. Combined treatment (UFT+FA+ oxaliplatin) reduced tumor weight by 39% compared to oxaliplatin alone ($q=4.256$, $p<0.05$) or UFT+FA ($q=4.230$, $p<0.05$). Pathological examination of the tumors showed no difference between the four groups.

In this model, data concerning bidimensional tumor size (i.e. surface area) and tumor weight were very similar. To validate the method of measurement, we assessed the relation between tumor size and tumor weight at day 28. The strong correlation between them ($r=0.94$) indicated that tumor weight can be estimated by tumor surface area, according to the following equation: weight (in g)= $0.77 \times$ Size (in mm²).

Discussion

Treatment of colorectal cancer is based on 5-FU modulated by FA. Oral prodrugs of 5-FU were recently developed in order to simplify the modality of treatment. The preliminary results of two randomized studies^{5,6} indicate that oral UFT+FA is as active as, and less toxic than, the standard FUFOL i.v. regimen (5-FU and FA administered as a bolus for 5 consecutive days every 4 weeks). During the past few years, steady improvements in both the response rate and progression-free survival have been observed with 5-FU infusion, and with the development of new drugs such as oxaliplatin or CPT-11. A clear synergism between oxaliplatin and 5-FU has been demonstrated, both in preclinical studies⁹ and clinical studies. Indeed, when oxaliplatin was used alone, 10 and 20% response rates were observed in second- and first-line treatments, respectively,¹² and for combined 5FU+oxaliplatin response rates reached 20–40% in second-line treatment^{10,13} and up to 50% in first-line treatment.¹¹ Therefore, almost all ongoing studies with oxaliplatin are using it combined with 5-FU or other drugs in various regimens.¹⁴

As already stated, UFT is a mixture of tegafur and uracil, at a molar ratio of 1:4. Tegafur is a 5-FU prodrug, while uracil inhibits 5-FU degradation.¹⁵ This 1:4 5-FU/uracil ratio was retained for the UFT design on the basis of the optimal tumor/serum 5-FU levels measured in rats bearing AH-130 tumors.¹⁶ As previously observed, the antitumoral activity of UFT or 5-FU is enhanced by FA.³

Our study was designed to assess the expected beneficial effect of UFT combined with oxaliplatin. We chose the same animal model as we previously used to evaluate the 5-FU and oxaliplatin combination.⁹ The nude mice bearing human colon cancer HT29 cell

xenografts were given UFT *per os*, at a daily dosage of 20 mg/kg, because this dosage corresponds to the dose most widely used in animal models,^{15,17} although higher doses have been given in some experiments.³ For oxaliplatin, 10 mg/kg was given i.p. on day 1 and for FA, a low dose of 4 mg/kg/day was given on the basis of our previous results.⁹ The tumor growth inhibition noted with the combined treatment was significantly greater than that observed with oxaliplatin alone or UFT+FA, versus controls.

Conclusion

This study demonstrates the synergistic activity between UFT+FA and oxaliplatin, and therefore argues strongly in favor of the clinical use of this combined treatment in colon cancer patients.

References

1. Malik STA, Talbot D, Clarke PI, *et al.* Phase II trial of UFT in advanced colorectal and gastric cancer. *Br J Cancer* 1990; 62: 1023-5.
2. Daniels M, Diaz-Rubio E, Guillem V, *et al.* Phase II trial of UFT activity in pretreated breast cancer patients. *Jpn J Clin Oncol* 1993; 23: 363-5.
3. Rustum YM. Mechanism-based improvement in the therapeutic selectivity of 5FU prodrug alone and under conditions of metabolic modulation. *Oncology* 1997; 54 (suppl 1): 7-11.
4. Cao S, Franck C, Shirasaka T, Rustum YM. 5-Fluorouracil prodrug: role of anabolic and catabolic pathway modulation in therapy of colorectal cancer. *Clin Cancer Res* 1995; 1: 839-45.
5. Carmichael J, Popiela T, Radstone D, *et al.* Randomized comparative study of Orzel (oral uracil/tegafur plus leucovorin) versus parenteral 5FU plus leucovorin in patients with metastatic colorectal cancer. *Proc Am Soc Clin Oncol* 1999; 18: 264 (abstr).
6. Pazdur R, Douillard JY, Skilling JR, *et al.* Multicenter phase III study of 5FU or UFT in combination with leucovorin in patients with metastatic colorectal cancer. *Proc Am Soc Clin Oncol* 1999; 18: 263 (abstr).
7. Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. *Semin Oncol* 1998; 25 (suppl 5): 4-12.
8. Faivre S, Woynarowski JM. Oxaliplatin effects on DNA integrity and apoptosis induction in human tumor cells. *Proc Am Ass Cancer Res* 1998; 39: 158 (abstr 1081).
9. Raymond E, Buguet-Fagot C, Djelloul S, *et al.* Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor A337 in human colon, breast and ovarian cancers. *Anti-Cancer Drugs* 1997; 8: 876-85.
10. De Gramont A, Vignoud J, Tournigand C, *et al.* Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. *Eur J Cancer* 1997; 33A: 214-9.
11. De Gramont A, Figer A, Seymour M, *et al.* A randomized trial of leucovorin and 5FU with or without oxaliplatin in advanced colorectal cancer. *Proc Am Soc Clin Oncol* 1998; 17: 257 (abstr).
12. Becouarn Y, Rougier P. Clinical efficacy of oxaliplatin monotherapy: phase II trials in advanced colorectal cancer. *Semin Oncol* 1998; 25 (2 suppl 5): 23-31.
13. Bleiberg H, de Gramont A. Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer. *Semin Oncol* 1998; 25 (2 suppl 5): 32-9.
14. Ducreux M, Louvet C, Bekradda M, Cvitkovic E. Oxaliplatin for the treatment of advanced colorectal cancer: future directions. *Semin Oncol* 1998; 25 (2 suppl 5): 47-53.
15. Nio Y, Shiraishi T, Tsubono M, *et al.* Relationship of *in vivo* antitumor activities of fluorinated pyrimidines to thymidylate synthase activity and intratumoral concentrations of 5-Fluorouracil and uracil. *Anticancer Res* 1991; 11: 607-12.
16. Fujii S, Kitano S, Ikenaka K, Shirasaka T. Effects of coadministration of uracil or cytosine on the antitumor activity of clinical dose of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. *Gann* 1978; 70: 209-14.
17. Kurebayashi J, Nukatsuka M, Fujioka A, *et al.* Postsurgical oral administration of uracil and tegafur inhibits progression of micrometastasis of human breast cancer cells in nude mice. *Clin Cancer Res* 1997; 3: 653-9.

(Received 11 April 2000; revised form accepted 29 May 2000)